Whitehawk Therapeutics, Inc. increased its authorized board size from nine to ten directors and appointed Vijay Iyengar, M.D., as a Class III director effective September 9, 2026. Dr. Iyengar brings extensive oncology leadership experience from previous roles at Incyte Corporation and Novartis. As part of his appointment, he received an initial stock option award to purchase 76,080 shares, vesting monthly over three years, along with a $40,000 annual base retainer and standard indemnification. Whitehawk Therapeutics is a clinical-stage oncology company developing antibody-drug conjugate (ADC) cancer treatments.

Whitehawk Therapeutics reported a net loss of $16.6 million for the quarter ended June 30, 2026, compared to a $52.6 million loss in the prior year period. Research and development expenses decreased to $12.9 million from $48.8 million, primarily due to the absence of a $38.0 million upfront license fee paid to WuXi Biologics in 2025. The company ended the quarter with $190.0 million in cash, cash equivalents, and short-term investments, sufficient to fund operations into the second half of 2028 following an $87.5 million private placement equity financing announced in May 2026. Clinically, patient enrollment continues for Phase 1 trials of HWK-007 and HWK-016, while a Phase 1 trial for HWK-206 is scheduled to initiate in Q3 2026. The company also entered into an option agreement with Hangzhou DAC for CPT113 access and a collaboration with Biocytogen for bispecific antibody ADC development. Whitehawk Therapeutics operates as a clinical-stage oncology therapeutics company focused on developing antibody drug conjugate cancer treatments.